Article Text
Statistics from Altmetric.com
Q In patients with recent onset mild asthma, what is the incremental cost effectiveness of early intervention with budesonide compared with usual care?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★☆☆☆ Respirology ★★★★★★☆ Allergy ★★★★★☆☆
METHODS
Design:
cost effectiveness analysis of a randomised controlled trial (Inhaled Steroid as Regular Therapy in Early Asthma [START] study).
Allocation:
{concealed*}†.
Blinding:
blinded {patients, clinicians, data collectors, outcome assessors, data analysts, and monitoring committee}†.*
Follow up period:
3 years.
Setting:
{499 sites in 32 countries}‡.
Patients:
7241 patients (mean age 24 y, 54% women; based on 7165 patients) who had received a diagnosis of asthma ⩽2 years before randomisation and had mild persistent asthma (ie, ⩾1 symptom such as wheeze, cough, or chest tightness per week, but not as often as every day, during the previous 3 mo) and airway reversibility. Exclusion criteria: significant comorbidity.
Interventions:
budesonide (Pulmicort Turbuhaler, AstraZeneca, London, UK), 400 …
Linked Articles
- Glossary